Bristol Myers, Schizophrenia
STAT · 4d
FDA approves schizophrenia drug that could alter how disorder is treated
Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works by stimulating a pair of muscarinic receptors in the brain, that, in turn, control the release of a brain chemical called acetylcholine.
Wall Street Journal · 4d
Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel treatment for schizophrenia. Bristol-Myers shares stood about 6% higher in recent premarket trading,
Yahoo · 3d
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s the first novel treatment for the debilitating mental disorder in over seven decades.
YAHOO!Finance · 3d
FDA approves new Bristol Myers Squibb schizophrenia drug
Shares of Bristol Myers Squibb (BMY) are surging after the FDA approved the pharmaceutical giant's schizophrenia drug, making it the first new drug-related approach for the disease in 30 years. Morning Brief Hosts Seana Smith and Madison Mills report more on the story and dig into how the drug works.
ScienceAlert · 9h
First New Schizophrenia Treatment in Decades a Much-Needed Alternative
"This drug takes the first new approach to schizophrenia treatment in decades," Tiffany Farchione, a top official in the US Food and Drug Administration (FDA), said in a statement Thursday. "This approval offers a new alternative to the antipsychotic medications people with schizophrenia have previously been prescribed,
Some results have been hidden because they may be inaccessible to you
Show inaccessible results